Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$16.85 - 0.28 (1.63%)
Exchange :NASDAQ
Volume :22,578
Today's Open$17.10
Previous Close$17.13
Data as of September 22, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $16.85 with a 52 week high of $26.36 and a 52 week low of $8.00.

Recent Press Releases

September 20, 2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 read more

September 14, 2017

/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ read more

September 11, 2017

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference read more

Upcoming Events


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.